Skip to main content

Advertisement

Table 2 Comparative risk for cardiovascular events between dapagliflozin and empagliflozin (reference)

From: Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study

  Dapagliflozin, n (incidence rate)a Empagliflozin, n (incidence rate)a Crude HR Adjusted HR
Composite outcome 128 (12.3) 197 (16.3) 0.75 (0.60–0.93) 0.91 (0.73–1.14)
Specific outcome     
 Cardiovascular mortality 3 (0.3) 7 (0.6) 0.46 (0.12–1.76) 0.54 (0.14–2.12)
 Myocardial infarction 33 (3.1) 53 (4.3) 0.70 (0.46–1.09) 0.77 (0.49–1.19)
 Ischemic stroke 56 (5.3) 63 (5.2) 1.03 (0.72–1.48) 1.15 (0.80–1.65)
 Heart failure 52 (4.9) 109 (9.0) 0.55 (0.39–0.76) 0.68 (0.49–0.95)
  1. aIncidence rate was calculated by 1000 person-years